Opko Health Inc (OPK)

[tomsylver]

OPKO Licensee TESARO Rated ‘BUY’ at Jefferies

Jefferies Starts Tesaro (TSRO) at Buy ( http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Tesaro+(TSRO)+at+Buy/9891240.html )

October 7, 2014 7:19 AM EDT

Jefferies initiates coverage on Tesaro (NASDAQ: TSRO) with a Buy rating and a price target of $40.00.

Analyst Eileen Flowers comments, "With our ~$1B peak sales est for TSRO's late-stage products rolapitant ($300M) & niraparib ($700M) based on our expert discussions, we see 50% upside potential from current levels. If rolapitant expands the market (peak sales of ~$500M), we see ~25% upside beyond our PT. Given 12 month underperformance (-32% for TSRO vs. +38% for BTK), we view TSRO's current valuation offers an attractive entry point ahead of clinical/regulatory catalysts starting in mid-2015."